• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

    4/25/23 1:04:49 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CERE alert in real time by email
    SC 13D/A 1 d501742dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Cerevel Therapeutics Holdings, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    15678U 128

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 25, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

     

     

     

    1

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    *

    information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).

     

     

     


    CUSIP No. 15678U 128   

    13D

       Page 2 of 5 Pages

     

      1.    

      Names of Reporting Persons

     

      Perceptive Advisors LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      AF

      5.  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      9,918,068

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      9,918,068

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,918,068

    12.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (9)

     

      6.3%%(1)

    14.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Calculated based on 156,656,668 shares of Common Stock outstanding as of February 10, 2023 as reported on the Issuer’s Form 10-K, filed on February 22, 2023.


    CUSIP No. 15678U 128   

    13D

       Page 3 of 5 Pages

     

      1.    

      Names of Reporting Persons

     

      Joseph Edelman

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      AF

      5.  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      6.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      170,317

         8.  

      Shared Voting Power

     

      10,088,385

         9.  

      Sole Dispositive Power

     

      170,317

       10.  

      Shared Dispositive Power

     

      10,088,385

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      10,088,385

    12.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (9)

     

      6.4%(1)

    14.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Calculated based on 156,656,668 shares of Common Stock outstanding as of February 10, 2023 as reported on the Issuer’s Form 10-K, filed on February 22, 2023.


    CUSIP No. 15678U 128   

    13D

       Page 4 of 5 Pages

     

      1.    

      Names of Reporting Persons

     

      Perceptive Life Sciences Master Fund, Ltd.

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      WC

      5.  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      6.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      9,918,068

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      9,918,068

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,918,068

    12.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (9)

     

      6.3%(1)

    14.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Calculated based on 156,656,668 shares of Common Stock outstanding as of February 10, 2023 as reported on the Issuer’s Form 10-K, filed on February 22, 2023.


    CUSIP No. 15678U 128   

    13D

       Page 5 of 5 Pages

     

    Explanatory Note

    The Reporting Persons are filing this Amendment No. 1 to the Schedule 13D filed on April 21, 2023 (the “Schedule 13D”) solely to amend and restate Item 4 of the Schedule 13D.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is amended and restated in its entirety as follows:

    In connection with and pursuant to a liquidating distribution by ARYA Sciences Holdings II (the “Sponsor”) on April 11, 2023 (the “Sponsor Distribution”), the Master Fund received 3,406,341 shares of Common Stock and Perceptive SP(A), L.P. (the “Co-Investment Fund”) received 851,585 shares of Common Stock. In connection with and pursuant to a distribution by the Co-Investment Fund of all of the shares of Common Stock it received in the Sponsor Distribution (the “Co-Invest Distribution” and together with the Sponsor Distribution, the “Distributions”), which immediately followed the Sponsor Distribution, Mr. Edelman received 170,317 shares of Common Stock, which are held by C2 Life Sciences LLC.

    Each Reporting Person expects to continuously review such person’s investment in the Issuer and, depending on various factors including, but not limited to, the price of the shares of Common Stock, the terms and conditions of the transaction, prevailing market conditions and such other considerations as such Reporting Person deems relevant, may at any time or from time to time, and subject to any required regulatory approvals, acquire additional shares of Common Stock, preferred stock or other securities convertible into or exercisable or exchangeable for Common Stock from time to time on the open market, in privately-negotiated transactions, directly from the Issuer, or upon the exercise or conversion of securities convertible into or exercisable or exchangeable for Common Stock.

    Each Reporting Person also may, at any time, subject to compliance with applicable securities laws and regulatory requirements dispose or distribute some or all of its of his Common Stock or such other securities as it or he owns or may subsequently acquire depending on various factors, including, but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives.

    Each Reporting Person may from time to time discuss with the Issuer’s management, directors, other shareholders and others, the Issuer’s performance, business, strategic direction, capital structure, product development program, prospects and management, as well as various ways of maximizing stockholder value, which may or may not include extraordinary transactions. Perceptive Advisors may in the future engage in discussions with the Issuer and third parties about potential strategic transactions; however, Perceptive Advisors is not currently aware of or participating in any such discussions.

    Except as reported herein, other than as noted above, no Reporting Person, as a stockholder of the Issuer, has any plans or proposals that relates or would result in any of the transactions or other matters specified in clauses (a) though (j) of Item 4 of Schedule 13D. Each Reporting Person may, at any time and from time to time, review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto.

    The information set forth below in Item 6 of the Schedule 13D is incorporated by reference into this Item 4.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 25, 2023

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
    Name:   Joseph Edelman
    Title:   Managing Member
    /s/ Joseph Edelman
    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By: Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
    Name:   Joseph Edelman
    Title:   Managing Member
    Get the next $CERE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CERE

    DatePrice TargetRatingAnalyst
    12/8/2023$45.00Outperform → Market Perform
    TD Cowen
    11/20/2023$25.00Neutral
    JP Morgan
    9/28/2023$33.00Overweight
    Piper Sandler
    8/3/2023$36.00 → $31.00Buy → Neutral
    BofA Securities
    5/4/2023$30.00Equal Weight → Overweight
    Wells Fargo
    4/10/2023Outperform
    TD Cowen
    3/17/2023$40.00 → $29.00Overweight → Neutral
    JP Morgan
    3/16/2023$22.00Hold
    Berenberg
    More analyst ratings

    $CERE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cerevel Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cerevel Therapeutics from Outperform to Market Perform and set a new price target of $45.00

      12/8/23 7:38:43 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on Cerevel Therapeutics with a new price target

      JP Morgan resumed coverage of Cerevel Therapeutics with a rating of Neutral and set a new price target of $25.00

      11/20/23 7:22:24 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Cerevel Therapeutics with a new price target

      Piper Sandler initiated coverage of Cerevel Therapeutics with a rating of Overweight and set a new price target of $33.00

      9/28/23 8:09:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.

      15-12G - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/12/24 7:30:56 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

      EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/6/24 12:15:03 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

      EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/6/24 12:15:15 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie Completes Acquisition of Cerevel Therapeutics

      Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it

      8/1/24 8:23:00 AM ET
      $ABBV
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process

      NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to clo

      5/17/24 7:12:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

      Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unrav

      4/18/24 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 6:25:19 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 4:52:52 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 4:51:04 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Koppel Adam bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:12 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gordon Christopher R bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:16 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bain Capital Investors Llc bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:09 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

      Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie

      6/15/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

      Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f

      5/10/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

      CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished legal executive, Mr. Akamine brings significant healthcare and biopharmaceutical experience to the role. He joins Cerevel from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance. 

      5/4/21 7:00:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Financials

    Live finance-specific insights

    See more
    • AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

      Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N

      12/6/23 4:30:00 PM ET
      $ABBV
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

      CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl

      10/13/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

      Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) --  Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updat

      8/2/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

      SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      8/5/24 6:12:07 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

      SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      8/5/24 4:30:55 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      5/10/24 10:03:20 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care